Study of ATEZOLIZUMAB Combination CARBOPLATIN + PACLITAXEL + BEVACIZUMAB in EGRF Mutation or ALK Translocation NSCLC
Condition: Non-small Cell Lung Cancer Interventions: Drug: Atezolizumab(Tecentriq); Drug: Pemetrexed; Drug: Bevacizumab; Drug: Carboplatin; Drug: Paclitaxel; Drug: Carboplatin or cisplatin Sponsor: Samsung Medical Center Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
More News: Alimta | Avastin | Cancer | Cancer & Oncology | Non-Small Cell Lung Cancer | Research | Study | Translocation